Close

The clinical trials session

Reading Time: 3 minutes A very much ‘must report on’ session of the 23rd International Symposium on ALS/MND was the clinical trials and trial design session. There are many reasons that make this an interesting session – perhaps the most eagerly anticipated were the presentations on the NP001 study and the results of the stem cell safety trial: NP001…

Encouraging NP001 clinical trial results for MND

Reading Time: 3 minutes Promising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested that NP001 is safe, well tolerated and could be beneficial for MND. Following these encouraging results, Neuraltus plan to begin a larger, Phase III trial of NP001 in the second half…

Clinical trial low down, down under

Reading Time: 3 minutes “After a time where patients and sponsors of trials alike had become disheartened about the lack of positive clinical trials, it is exciting to see so many positives, including the recently approved Neudexta, and the dexpramipexole study”, commented Professor Robert Miller from the Forbes Norris ALS/MDA centre in San Francisco opening the discussions on clinical…